Search Results - peptide+inhibitor

4 Results

Sort By:

A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer

Abstract: The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation, tissue homeostasis, and stem cell functions. This axis has been recently listed as one of the top 10 signaling pathways altered in human cancer. Its role in modulating cell growth and proliferation is mediated...

Published: 4/8/2024 | Inventor(s): Ramiro Iglesias-Bartolome, Yao Yuan

Keywords(s): Cancer Progression, Hippo Signaling Pathway, Iglesias-Bartolome, Peptide Inhibitor, TAZ, TEAD, YAP1, Yes-Associated Protein 1

Category(s): TherapeuticArea > Oncology, Application > Research Materials, Collaboration Sought > Licensing

Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain

Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types. Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics. Plk1 contains an allosteric domain, known as the polo-box domain (PBD),...

Published: 5/22/2024 | Inventor(s): Terrence Burke, Wen-Jian Qian, Kyung Lee, Jung-Eun Park, James Kelley

Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)

Published: 5/22/2024 | Inventor(s): Terrence Burke, Jung-Eun Park, Wen-Jian Qian, Fa Liu, Kyung Lee

Keywords(s): Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes...

Published: 8/14/2024 | Inventor(s): Louis Staudt, Yiban Yang, Federico Bernal

Keywords(s): ABC DLBCL, Activated B Cell-like, Autoimmune, Bernal, CANCER, Diffuse Large B Cell Lymphoma, INFLAMMATORY, Linear Ubiquitin-chain Assembly Complex, LUBAC, NF-κB, Non-Hodgkin’s Lymphoma, Peptide Inhibitor, Staudt, therapeutic

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology